文献速递慢性肾脏病血液净化与透析

降低胆固醇的新药:对肾内科医生的启示

New agents to reduce cholesterol levels: implications for nephrologists.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

他汀和依折麦布可有效降低慢性肾脏病(CKD)患者的心血管疾病负担,但许多患者仍发生心血管事件。前蛋白转化酶枯草溶菌素/kexin 9型(PCSK9)抑制剂(单克隆抗体、反义寡核苷酸、siRNA)可在最大化他汀治疗基础上大幅降低胆固醇。Evolocumab和alirocumab显著降低心血管风险且无相关安全问题,Inclisiran的II期研究显示显著降胆固醇疗效,但在CKD人群中的经验有限。

要点

  • PCSK9抑制剂可在最大化他汀治疗基础上大幅降低胆固醇水平。
  • Evolocumab和alirocumab显著降低心血管风险且无相关安全问题。
  • Inclisiran的II期研究显示显著降胆固醇疗效。

核心结论

  • PCSK9抑制可在最大化他汀治疗基础上大幅降低胆固醇,有望减少CKD患者心血管负担,但对透析患者结局改善存疑。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 他汀和依折麦布可有效降低CKD患者心血管疾病负担,但许多患者仍死亡或发生心血管事件,晚期CKD尤甚。
  • PCSK9是丝氨酸蛋白酶,通过靶向低密度脂蛋白受体至溶酶体降解而诱导其降解。
  • 抑制PCSK9可在最大化他汀治疗基础上大幅降低胆固醇水平,手段包括单克隆抗体、反义寡核苷酸和siRNA。
  • Evolocumab和alirocumab显著降低心血管疾病风险且无相关安全问题;Inclisiran的II期研究显示显著降胆固醇疗效。
  • 在CKD人群中的经验有限;透析患者血管钙化为主,该策略能否改善其结局存疑。

临床怎么用

  • 对最大化他汀治疗后胆固醇仍不达标或心血管事件高危的CKD患者,可考虑PCSK9抑制剂。
  • 两种单克隆抗体已获批临床使用但价格仍很高。
  • 透析患者血管钙化为主,PCSK9抑制剂的获益尚不明确。

局限性

  • 在CKD人群中的经验有限。
  • 对透析患者结局改善存疑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Statins and ezetimibe effectively reduce the burden of cardiovascular (CV) disease in patients with chronic kidney disease (CKD). Unfortunately, many subjects still die or have CV events despite cholesterol-lowering therapy. This is particularly true in patients with more advanced CKD. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that induces the degradation of the low-density lipoprotein receptor by targeting it for lysosomal destruction. Its inhibition causes a dramatic fall in cholesterol levels on top of maximized statin therapy. This goal is obtained with different therapeutic approaches, spanning from monoclonal antibodies to non sense oligonucleotides and silencing RNA (siRNA). Two human, monoclonal antibodies are approved for clinical use; they are still very expensive. Both agents significantly lower cholesterol levels. Evolocumab and alirocumab reduce significantly the risk for CV disease without relevant safety issues. Inclisiran is an siRNA molecule that produces PCSK9-specific RNA silencing. Data from a Phase II study showed significant cholesterol-lowering efficacy. The experience accumulated so far is limited in the CKD population. PCSK9 inhibition also has the potential to reduce the burden of CV in this subset by obtaining a much greater decrease in serum cholesterol compared with statin therapy or ezetimibe. Doubts exist that this approach will improve the outcome of dialysis patients, in whom vascular calcifications predominate.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Del Vecchio L, Baragetti I, Locatelli F, et al. New agents to reduce cholesterol levels: implications for nephrologists. Nephrol Dial Transplant. 2020. PMID: 30753594. doi:10.1093/ndt/gfz013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。